Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches

Trends in Genetics

Volumn 32, Issue 2, 2016, Pages 127-137

  Hu, Xueda ^a   Zhang, Zemin ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Cancer genome; Drug resistance mechanisms; Functional genomic screening

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CETUXIMAB; CRIZOTINIB; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FOCAL ADHESION KINASE; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN TYROSINE KINASE; SCATTER FACTOR; SOMATOMEDIN RECEPTOR; TEMOZOLOMIDE; TRANSCRIPTION FACTOR GATA 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

CANCER GENETICS; CANCER RESISTANCE; COLORECTAL CANCER; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; GLIOMA; HUMAN; LUNG ADENOCARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR MICROENVIRONMENT; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; GENOMICS; PROCEDURES;

ANIMALS; DRUG RESISTANCE, NEOPLASM; GENOMICS; HUMANS;

EID: 84958619618     PISSN: 01689525     EISSN: 13624555     Source Type: Journal    
DOI: 10.1016/j.tig.2015.11.003     Document Type: Review

References (92)

1. Garraway L.A., Lander E.S. Lessons from the cancer genome. Cell 2013, 153:17-37.
2. Bedard P.L., et al. Tumour heterogeneity in the clinic. Nature 2013, 501:355-364.
3. Awad M.M., et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 2013, 368:2395-2401.
4. Montagut C., et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 2012, 18:221-223.
5. Engelman J.A., et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 2006, 116:2695-2706.
6. Sequist L.V., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3:75ra26.
7. Niederst M.J., Engelman J.A. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci. Signal. 2013, 6:re6.
8. Wang Z., et al. Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:9990-9995.
9. Lee H.J., et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014, 26:207-221.
10. Zhang Z., et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 2012, 44:852-860.
11. Konieczkowski D.J., et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014, 4:816-827.
12. Straussman R., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
13. Hirata E., et al. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer cell 2015, 27:574-588.
14. Sharma S.V., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
15. Zeller C., et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012, 31:4567-4576.
16. Zhang Y.W., et al. Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer. Epigenetics 2014, 9:896-909.
17. Garrido-Laguna I., et al. A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Inves. New Drugs 2013, 31:1257-1264.
18. Bauer S., et al. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br. J. Cancer 2014, 110:1155-1162.
19. Falchook G.S., et al. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Inves. New Drugs 2013, 31:1192-1200.
20. Glasspool R.M., et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br. J. Cancer 2014, 110:1923-1929.
21. Vogelstein B., et al. Cancer genome landscapes. Science 2013, 339:1546-1558.
22. Boehm J.S., Hahn W.C. Towards systematic functional characterization of cancer genomes. Nat. Rev. Genet. 2011, 12:487-498.
23. Abaan O.D., et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 2013, 73:4372-4382.
24. Liu H., et al. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol. Cancer Ther. 2010, 9:1080-1091.
25. Park E.S., et al. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol. Cancer Ther. 2010, 9:257-267.
26. Reinhold W.C., et al. NCI-60 whole exome sequencing and pharmacological CellMiner analyses. PLoS ONE 2014, 9:e101670.
27. Varma S., et al. High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner. PLoS ONE 2014, 9:e92047.
28. McDermott U., et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Nat. Acad. Sci. U.S.A. 2007, 104:19936-19941.
29. Sos M.L., et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J. Clin. Invest. 2009, 119:1727-1740.
30. Cheung H.W., et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Nat. Acad. Sci. U.S.A. 2011, 108:12372-12377.
31. Wilson T.R., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.
32. Greshock J., et al. Molecular target class is predictive of in vitro response profile. Cancer Res. 2010, 70:3677-3686.
33. Barretina J., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
34. Garnett M.J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
35. Klijn C., et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 2015, 33:306-312.
36. Yang X., et al. A public genome-scale lentiviral expression library of human ORFs. Nat. Methods 2011, 8:659-661.
37. Wilson F.H., et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer cell 2015, 27:397-408.
38. Johannessen C.M., et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 2013, 504:138-142.
39. Johannessen C.M., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
40. Sharifnia T., et al. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:18661-18666.
41. Serra V., et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J. Clin. Invest. 2013, 123:2551-2563.
42. Moody S.E., et al. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene 2015, 34:2061-2071.
43. Martz C.A., et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci. Signal. 2014, 7:ra121.
44. Winter P.S., et al. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Sci. Signal. 2014, 7:ra122.
45. Iorns E., et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008, 13:91-104.
46. Berns K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
47. Mendes-Pereira A.M., et al. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2730-2735.
48. Wetterskog D., et al. Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers. Oncogene 2014, 33:966-976.
49. de Bruin E.C., et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov. 2014, 4:606-619.
50. Holzel M., et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010, 142:218-229.
51. Huang S., et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell 2012, 151:937-950.
52. Sun C., et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014, 508:118-122.
53. Whitehurst A.W., et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007, 446:815-819.
54. Zhu Y.X., et al. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood 2011, 117:3847-3857.
55. + leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 2010, 18:74-87.
56. Prahallad A., et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
57. Corcoran R.B., et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013, 23:121-128.
58. Brough R., et al. Functional viability profiles of breast cancer. Cancer Discov. 2011, 1:260-273.
59. Martin S.A., et al. Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res. 2011, 71:1836-1848.
60. Herrera-Abreu M.T., et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 2013, 3:1058-1071.
61. Kessler J.D., et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012, 335:348-353.
62. Kumar M.S., et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 2012, 149:642-655.
63. Sanchez-Rivera F.J., Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. Nat. Rev. Cancer 2015, 15:387-395.
64. Wagle N., et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 2011, 29:3085-3096.
65. Van Allen E.M., et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014, 4:94-109.
66. Ahronian L.G., et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer discov. 2015, 5:358-367.
67. Wagle N., et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014, 4:61-68.
68. Patch A.M., et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015, 521:489-494.
69. Johnson B.E., et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014, 343:189-193.
70. Haibe-Kains B., et al. Inconsistency in large pharmacogenomic studies. Nature 2013, 504:389.
71. Hatzis C., et al. Enhancing reproducibility in cancer drug screening: how do we move forward?. Cancer Res. 2014, 74:4016-4023.
72. Liu X., et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol. 2012, 180:599-607.
73. Crystal A.S., et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014, 346:1480-1486.
74. Tentler J.J., et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 2012, 9:338-350.
75. Hidalgo M., et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014, 4:998-1013.
76. Li S., et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013, 4:1116-1130.
77. Lodhia K.A., et al. Prioritizing therapeutic targets using patient-derived xenograft models. Bioch. Biophys. Acta 2015, 1855:223-234.
78. Julien S., et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res. 2012, 18:5314-5328.
79. Chua C.W., et al. Single luminal epithelial progenitors can generate prostate organoids in culture. Nat. Cell Biol. 2014, 16:951-961. 951-954.
80. van de Wetering M., et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015, 161:933-945.
81. Sato T., et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009, 459:262-265.
82. Kuratnik A., Giardina C. Intestinal organoids as tissue surrogates for toxicological and pharmacological studies. Biochem. Pharmacol. 2013, 85:1721-1726.
83. Gao D., et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014, 159:176-187.
84. Karthaus W.R., et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 2014, 159:163-175.
85. Boj S.F., et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 2015, 160:324-338.
86. Montero J., et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 2015, 160:977-989.
87. Iadevaia S., et al. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res. 2010, 70:6704-6714.
88. Yan H., et al. A formal model for analyzing drug combination effects and its application in TNF-alpha-induced NFkappaB pathway. BMC Sys. Biol. 2010, 4:50.
89. Miller M.L., et al. Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets. Sci. Signal. 2013, 6:ra85.
90. Niepel M., et al. Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines. Sci. Signal. 2013, 6:ra84.
91. Bozic I., Nowak M.A. Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:15964-15968.
92. Zhao B., et al. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov. 2014, 4:166-174.